The quarter beat the standing estimates, but the forward reset is the material news. Adjusted EPS of $1.66 exceeded the published consensus of about $1.45, while revenue of $801.7 million was roughly $14 million above the published consensus near $787 million. That is a solid reported-quarter beat—but it does not offset the reduction in the growth path investors had been using for the rest of 2026.
| Metric | Q2 2026 actual | Comparison | What changed |
|---|---|---|---|
| Revenue | $801.7M | $649.1M; published consensus ~$787M | +23.5% YoY; modest revenue beat (Income Statement) |
| Adjusted diluted EPS | $1.66 | $1.17 prior year; published consensus ~$1.45 | 42% YoY growth; $0.21 beat (Non-GAAP reconciliation) |
| Omnipod revenue | $795.9M | $639.0M | +24.6% reported, +23.8% constant currency (Revenue by geography and product) |
| U.S. Omnipod revenue | $544.1M | $453.2M | +20.1% in Q2, but outlook now calls for slower growth (Revenue by geography and product) |
| Adjusted operating margin | 19.3% | 17.8% | +150 basis points YoY, despite correction-related costs (Non-GAAP reconciliation) |
| FY 2026 total revenue growth guide | 20%–22% constant currency | 21%–23% previously | Cut by 1 percentage point at both ends (2026 Outlook) |
| FY 2026 U.S. Omnipod growth guide | 17%–19% | 20%–22% previously | Cut by 3 percentage points at both ends (2026 Outlook) |
| FY 2026 international Omnipod growth guide | 30%–32% | 26%–28% previously | Raised, but not enough to preserve the total-company outlook (2026 Outlook) |
| Free cash flow | $145.4M | $229.4M | Down 37% YoY as operating cash flow and capital spending moved unfavorably (Free Cash Flow reconciliation) |
The downgrade is concentrated in the core U.S. business. Q2 U.S. Omnipod revenue still grew 20.1%, but management reduced its full-year U.S. growth range to 17%–19% from 20%–22% and set Q3 at 14%–16%. International guidance increased, yet total Omnipod growth still falls to 21%–23% from 22%–24%. Put plainly: better overseas demand is partly cushioning, not eliminating, a slower expected U.S. ramp (2026 Outlook; Revenue by geography and product).
Profitability held up better than sales guidance. The company kept its target for roughly 100 basis points of adjusted operating-margin expansion and raised adjusted EPS-growth guidance to more than 30% from more than 25%. Q2 adjusted operating margin expanded to 19.3% from 17.8%. That limits the damage from the revenue reset, but it changes the mix of the outlook: more earnings help is now expected from margins rather than the previously assumed U.S. sales growth (2026 Outlook; Non-GAAP reconciliation).
Reported GAAP earnings include a new cost that should not be ignored. GAAP EPS was $1.37, versus adjusted EPS of $1.66, with $25.0 million of voluntary medical-device-correction warranty and related costs accounting for most of the gap. Management excludes these costs from adjusted results, but they are cash-economic consequences of the March and May 2026 corrections rather than a purely accounting item (Non-GAAP reconciliation; Adjusted EBITDA reconciliation).
Cash generation softened despite the earnings beat. Free cash flow declined to $145.4 million from $229.4 million, as operating cash flow fell to $202.2 million and capital expenditures rose to $56.8 million. Cash also declined to $534.9 million at June 30 from $716.1 million at year-end, while long-term debt was essentially unchanged at $929.5 million. This is not presented as a liquidity problem, but it provides less reinforcement for the otherwise strong earnings result (Free Cash Flow reconciliation; Balance Sheet).
Net read: the backward-looking beat is real, but the revised U.S. growth assumption is more consequential. The filing shifts the 2026 narrative from accelerating domestic Omnipod growth to slower U.S. expansion partly offset by international strength and margin execution. That is worse than the market's pre-release growth framework, even with above-consensus Q2 revenue and adjusted EPS.
Read the original 8-K on SEC EDGAR ↗